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Abstract
OBJECTIVES: Availability of donor lungs suitable for transplant falls short of current demand and contributes to waiting list mortality.
Ex vivo lung perfusion (EVLP) offers the opportunity to objectively assess and recondition organs unsuitable for immediate transplant.
Identifying robust biomarkers that can stratify donor lungs during EVLP to use or non-use or for specific interventions could further im-
prove its clinical impact.
METHODS: In this pilot study, 16 consecutive donor lungs unsuitable for immediate transplant were assessed by EVLP. Key inflammatory
mediators and tissue injury markers were measured in serial perfusate samples collected hourly and in bronchoalveolar lavage fluid (BALF)
collected before and after EVLP. Levels were compared between donor lungs that met criteria for transplant and those that did not.
RESULTS: Seven of the 16 donor lungs (44%) improved during EVLP and were transplanted with uniformly good outcomes. Tissue and vas-
cular injury markers lactate dehydrogenase, HMGB-1 and Syndecan-1 were significantly lower in perfusate from transplanted lungs. A
model combining IL-1b and IL-8 concentrations in perfusate could predict final EVLP outcome after 2 h assessment. In addition, perfusate
IL-1b concentrations showed an inverse correlation to recipient oxygenation 24 h post-transplant.
CONCLUSIONS: This study confirms the feasibility of using inflammation and tissue injury markers in perfusate and BALF to identify donor
lungs most likely to improve for successful transplant during clinical EVLP. These results support examining this issue in a larger study.
Keywords: Lung transplant • EVLP • Lung injury • Inflammation • Biomarkers
INTRODUCTION
Normothermic ex vivo lung perfusion (EVLP) has emerged as a
promising technique to expand the donor pool by assessing and
reconditioning donor lungs previously considered unsuitable for
transplant [1]. The lung is highly susceptible to injury in the crit-
ical care environment, and in the hours or days leading up to the
donor’s demise it may be exposed to the sequelae of brain-stem
death together with infection, aspiration, barotrauma, fluid over-
load or multiple transfusions [2–4]. Because the extent of lung in-
jury is difficult to assess at the time of organ procurement, donor
acceptance criteria are therefore conservative and poor discrim-
inators of injury and infection in the donor lung [5]. The
increased use of extended-criteria donors may further elevate
the risk of primary graft dysfunction (PGD) and other more se-
vere postoperative complications [6–8].
The use of ex vivo reconditioned donor lungs is steadily grow-
ing and now accounts for about 20% of the activity in some es-
tablished centres [9–11]. The decision to accept organs for
transplant after EVLP has, however, been based on the same
questionable physiological measures and organ appearance used
during standard procurement. Reported discard rates of 10–60%
of perfused lungs suggest that some donor lungs may be in-
appropriately used or declined for transplant after EVLP [1].
In donor lungs transplanted without ex vivo evaluation, there is
an established relationship between their inflammatory burden
and early outcome [12–15]. However, this phenomenon has not
been as extensively investigated during EVLP.
In this proof-of-concept study, we evaluated a panel of inflam-
matory mediators and tissue injury-associated proteins in both†These authors contributed equally to this work.
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perfusate and bronchoalveolar lavage fluid (BALF) from human
donor lungs undergoing clinical EVLP with intent for transplant.
The panel was based on our own previous work and on available
studies of biological markers in standard lung transplant and pre-
clinical and clinical observations during EVLP. The aim was to as-
sess the potential for specific protein markers in perfusate and
BALF to distinguish which donor lungs, initially deemed unsuit-
able for immediate transplantation are most likely to successfully
recondition during EVLP and thereby provide a basis for further
investigations in a larger validation cohort.
MATERIALS AND METHODS
Study design
We conducted a prospective observational study investigating
protein expression in donor lungs exposed to a standardized
EVLP protocol. Approval was granted by our local research ethics
committee, and informed consent for research was obtained
from donor families and lung transplant recipients (REC 09/
H0905/10).
Ex vivo lung perfusion protocol
Adult donor lungs deemed unsuitable for lung transplant by all
five UK lung transplant centres but meeting strict EVLP criteria
were included in the study (Supplementary Table S1), the results
of which were previously published by our group [16]. Lungs
were procured in a routine fashion and transported to our insti-
tution. The EVLP assessment followed a standardized acellular
protocol using the Toronto technique with a closed left atrium
and reduced perfusate flow, previously described in detail [3, 16].
Transplant suitability was assessed hourly during perfusion. Lungs
meeting transplant criteria (Supplementary Table S2) at two con-
secutive time points were cooled and transplanted. Lungs
deemed to have futile prospects for improvement were taken off
the circuit and discarded. Two transplanted and five non-
transplanted lungs were perfused >_5h before a transplant decision
was made.
Sample collection and processing
A research BAL was performed for all lungs by wedging an adult
bronchoscope in a subsegmental bronchus of the right or left
lower lobe [17]. Saline (40 ml) was instilled through the suction
channel followed by gentle aspiration and sample collection
prior to commencing ventilation at the beginning of EVLP. This
process was repeated in the same lobe but in a different subseg-
mental bronchus before disconnecting the ventilation at the end
of perfusion. In addition, hourly perfusate samples of 2.5 ml were
collected until the assessment was stopped.
Protein expression analysis
All protein expressions measured in perfusate were adjusted to
the predicted total lung capacity (pTLC) of the donor as an esti-
mate of perfused donor lung volume and were reported as cor-
rected perfusate concentrations (pg/ml). The pTLC was calculated
in a routine fashion based on donor gender and height [18]. If
one lung was deemed unusable due to severe consolidation or
extensive contusion on inspection, or if the intended recipient
required a single lung transplant on a specific side, only one
lung was procured. For single-lung perfusions, the pTLC was ad-
justed to a factor of 0.55 for right lung and 0.45 for left lung per-
fusion [19].
Lactate dehydrogenase assay
Lactate dehydrogenase (LDH) levels were measured in perfusate
and BALF with a colorimetric LDH cytotoxicity assay kit accord-
ing to manufacturer’s instructions and reported as arbitrary units
(U) (Thermo Fisher Scientific Inc., Rockford, IL, USA).
Multiplex inflammatory cytokine array
Interleukin (IL)-1b, IL-6, IL-8, TNF-a, and IL-10 were analysed
with an MSD Multi-ArrayVR (Meso Scale Diagnostics, LLC,
Rockville, MD, USA). The assay was performed according to the
manufacturer’s instructions. Technical issues prevented reading
of perfusate samples from donor lung EVLP03; therefore, these
samples were excluded from the analysis.
Enzyme-linked immunosorbent assays
Syndecan-1, IL-33, S100A9 (all R&D Systems, Inc., Minneapolis,
MN, USA) and high-mobility group box-1 (HMGB-1) (Shino-Test
Corporation, Kanagawa, Japan) were measured with commer-
cially available ELISA kits according to the manufacturers’
instructions.
Statistical analysis
Donor characteristics and physiological parameters are expressed
as medians with interquartile ranges and were compared be-
tween transplanted and non-transplanted lungs using Mann–
Whitney U tests. Paired samples, start-end of perfusion, were
compared with Wilcoxon signed-ranks tests. Log protein expres-
sions were compared between transplanted and non-
transplanted lungs with multiple t-tests. Correlations between IL-
8 and IL-1b expressions and seven post-transplant outcomes
(PaO2:FiO2 24-h post-transplant; PGD3 at 72 h post-transplant;
ventilation time; intensive care unit stay hospital stay‘; percent of
predicted FEV1 at 6 months post-transplant; and percent of pre-
dicted FVC at 6 months post-transplant) were analysed by
Pearson’s correlation tests. The data were transformed back into
non-logged values for reporting as mean (T) for transplanted and
mean (NT) for non-transplanted lungs with standard deviations
(SD). Multiple testing of donor parameters, protein analyses, and
correlations was corrected using the Benjamini-Hochberg false
discovery rate (FDR) controlling procedure [20]. Because this was
a feasibility study aiming to identify potential markers for further
investigation in a validation cohort, an FDR corrected P-val-
ue <0.1 was deemed significant. Corrected P-values are reported.
A multiple logistic regression model was fitted using the 11 log
transformed protein covariates and their squared counterparts as
independent variables and the EVLP outcome as the dependent
variable. The optimal model was established by leave-one-out
cross-validation using the software package R from R Core
Team (2014) (R Foundation for Statistical Computing, Vienna,
Austria) [21].
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RESULTS
Study group and donor characteristics
Sixteen consecutive clinical EVLP assessments of lungs deemed
unacceptable for standard transplant were included in the study
(Table 1). Seven (44%) were accepted for transplant after EVLP as-
sessment and were implanted as four bilateral and three single-
lung procedures. Nine (56%) failed to achieve transplant criteria
and were excluded. The characteristics of the donor groups of
transplanted and non-transplanted lungs were not significantly
different and are shown in Tables 1 and 2.
Ex vivo lung perfusion outcomes
The median partial pressure of oxygen on 100% inspired oxygen
(PaO2:FiO2) at the end of EVLP was 516 (478–523) mmHg for
transplanted and 342 (322–392) mmHg for non-transplanted
donor lungs (Mann–Whitney U = 4, P = 0.02). The median
PaO2:FiO2 improvement after EVLP was 321 (186–362) mmHg in
transplanted donor lungs (Wilcoxon Z = -2.37, P = 0.03). No im-
provement was seen in lungs that failed assessment; the median
PaO2:FiO2 change was 20 (-42–94) mmHg, (Wilcoxon Z = -0.18,
P = 0.91) (Fig. 1).
Of the nine lungs that failed EVLP reconditioning, six displayed
worsening pulmonary oedema and two showed signs of persist-
ent hyperinflation and raised PVR, suggesting diffuse injury and a
degree of intrinsic emphysema. This suggestion was later verified
by a pathologist from pulmonary biopsies. Lastly, one set of lungs
was turned down due to heavy microbial contamination with
multiple gram-negative organisms identified in the tracheal
aspirate.
Transplant outcomes
In the seven donor lungs that were transplanted, perfusion and
ventilation parameters remained stable or improved during as-
sessment. The data on changes in lung compliance, airway resist-
ance, PVR, perfusate flow, and ventilation and perfusion
pressures are shown in Fig. 1.
None of the recipients required extracorporeal life support.
Two patients (29%) suffered from PGD (Grade 3) at 72 h post-
transplant. However, both patients responded well to standard
management. All seven recipients survived to hospital discharge.
One recipient died of severe pneumonia at 11 months post-
transplant due to an influenza infection unrelated to the EVLP
procedure. The other six (86%) remain alive and well >2 years
after transplant (Table 2).
Analysis of perfusate and bronchoalveolar lavage
fluid
Assessed lungs were divided into two groups based on decision
after EVLP: transplanted (n = 7) or non-transplanted (n = 9).
Decision on transplant suitability was based on strict criteria
summarized in Supplementary Table S2. Samples were analysed
retrospectively for protein expressions.
For an initial general assessment of tissue injury, we measured
LDH levels. LDH was found in substantially lower levels in perfus-
ate from lungs meeting criteria for transplant (T) after EVLP com-
pared to those that did not meet the criteria for transplant (NT)
lungs. Suitability for transplant was evident after 2 h of perfusion:
mean (T) = 0.150 U (SD 0.030, n = 14) and mean (NT) = 0.223 U
(SD 0.082, n = 18) [t(30) = 2.77, P = 0.03] (Fig. 2). The LDH
Table 1: Donor characteristics
Donor no. Age/
gender
Smoker Donor cause
of death
Donor type TLC (L) Micro on
offer
Radiographic
infiltrates
Secretions EVLP indication
EVLP 01 18 m No Diabetic coma DL DBD 7.30 Nil Bilateral Nil PaO2 <300 mmHg
EVLP 02 51 f Yes ICH DL DBD 4.31 Nil Clear Nil PaO2 <300 mmHg
EVLP 03 33 m Yes ICH DL DBD 7.14 Nil Left diffuse Purulent PaO2 <300 mmHg
EVLP 04 15 f No Hanging DL DCD 5.10 Nil Bilateral Nil PaO2 <300 mmHg
EVLP 05 52 m No ICH DL DBD 5.78 Nil Clear Mucopurulent PaO2 <300 mmHg
EVLP 06 57 m Yes ICH DL DBD 7.54 Nil Right basal Mucopurulent oedema
EVLP 07 52 f Yes ICH SL DBD 2.70 Nil Bibasal Purulent PaO2 <300 mmHg
EVLP 08 20 m Yes Hanging SL DBD 3.18 Nil Right basal Nil PV PaO2 <225 mmHg +
oedema
EVLP 09 36 m No Brain tumour SL DBD 3.11 Yesa Left diffuse Nil PaO2 <300 mmHg
EVLP 10 47 m No HBI DL DBD 6.74 Nil Clear Nil PaO2 <300 mmHg
EVLP 11 45 f No TBI DL DBD 6.18 Nil Clear Nil PV PaO2 <225 mmHg +
mild contusion RLL
EVLP 12 56 m No ICH DL DBD 6.50 Nil Clear Purulent PaO2 <300 mmHg
EVLP 13 18 f Yes ICH DL DCD 5.03 Nil Bilateral Mucopurulent oedema
EVLP 14 53 m Yes ICH DL DBD 7.06 Nil Clear Purulent PaO2 <300 mmHg
EVLP 15 48 f No ICH DL DBD 4.57 Nil Bibasal Purulent PaO2 <300 mmHg
EVLP 16 38 m Yes Hanging DL DCD 6.98 Nil Left basal Nil oedema
Shaded donor lungs were not transplanted after EVLP .
BALF: bronchoalveolar lavage fluid; EVLP : ex vivo lung perfusion; ICH: intracranial haemorrhage; HBI: hypoxic brain injury secondary to variceal bleed; TBI:
traumatic brain injury following a road traffic accident; DL: double lung perfusion; SL: single lung perfusion; DBD: organ donation after brain death; DCD:
organ donation after circulatory death; TLC: predicted total lung capacity of perfused lung; PaO2: partial pressure of arterial oxygen; PV: selective pulmonary
vein blood gas analyses; RLL: right lower lobe.
aSputum culture with moderate growth of Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae.
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Table 2: EVLP and transplant outcomes
Donor no. Optimized donor
PaO2:FiO2 (mmHg)
PaO2:FiO2 after
EVLP (mmHg)
Ischaemic
time (min)a
EVLP time
(min)b
Total time
ex vivo (min)c
Transplant PGD 3
at 72 h
90-day
survival
EVLP 01 149 521 345 290 1020 Yes–BL Yes Yes
EVLP 02 248 342 360 360 N/A No–emphysema
EVLP 03 209 167 330 270 N/A No–gross oedema
EVLP 04 222 426 450 360 870 Yes–SL No Yes
EVLP 05 167 440 320 330 N/A No–heavy gram-stain
in BALF
EVLP 06 357 525 395 240 582 Yes–SL No Yes
EVLP 07 178 557 315 255 1048 Yes–SL Yes Yes
EVLP 08 372 392 340 240 N/A No–emphysema
EVLP 09 293 330 430 300 N/A No–gross oedema
EVLP 10 171 291 305 300 N/A No–gross oedema
EVLP 11 526 452 340 330 N/A No–gross oedema
EVLP 12 191 512 395 220 785 Yes–BL No Yesd
EVLP 13 360 352 345 180 N/A No–gross oedema
EVLP 14 165 516 270 190 496 Yes–BL No Yes
EVLP 15 293 443 360 165 713 Yes–BL No Yes
EVLP 16 527 322 335 180 N/A No–gross oedema
Shaded donor lungs were not transplanted after EVLP.
PaO2:FiO2: the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen; EVLP: ex vivo lung perfusion; PGD: primary graft dysfunction at 72 h;
SL: single lung transplant; BL: bilateral lung transplant; N/A: not applicable; BALF: bronchoalveolar lavage fluid.
aStart of donor lung flush at procurement to start of pulmonary artery (PA) perfusion on EVLP circuit.
bStart of PA perfusion to disconnection from EVLP circuit.
cStart of donor lung flush at procurement to reperfusion in recipient.
dDeath due to H1N1 infection 11 months post-transplant.
Figure 1: Physiological characteristics of transplanted and non-transplanted EVLP donor lungs. Box and whisker plots with boxes showing medians with interquartile
range and whiskers at max and min. **P<0.05. EVLP; start time: point when the lung had been successfully rewarmed to 37 C in the beginning of the EVLP; end time:
point before start of cooling at the end of the EVLP.
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Figure 2: Protein expressions during EVLP in perfusate from transplanted and non-transplanted donor lungs. Protein levels expressed as medians with interquartile
ranges. **P<0.05. EVLP: ex vivo lung perfusion; LDH: lactate dehydrogenase; IL: interleukin; TNF-a: tumour necrosis factor alpha; HMGB-1: high-mobility group box-1;
Time: hours of ex vivo lung perfusion after start of pulmonary artery perfusion.
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perfusate levels remained significantly different when assessed
over all sample time points: mean (T) = 0.149 U (SD 0.033, n = 24)
and mean (NT) = 0.259 U (SD 0.088, n = 40) [t(62) = 5.45,
P < 0.001]. No difference in LDH levels was seen in BALF samples
collected pre- and post-perfusion.
To assess the integrity of the pulmonary vascular compart-
ment, we measured Syndecan-1 levels as a marker of endothelial
glycocaylx disruption. Syndecan-1 levels were significantly lower
in perfusate samples from transplanted donor lungs: mean
(T) = 111 (pg/ml) (SD 98, n = 24) compared to mean (NT) = 281
(pg/ml) (SD 219, n = 40) [t(62) = 4.14, P < 0.001] (Fig. 3).
We noted a similarly consistent pattern towards lower release
of proinflammatory cytokines into the circulating perfusate from
transplanted compared to non-transplanted lungs. The average
level of IL-8 was nearly eight times higher in perfusate samples
from non-transplanted lungs: mean (T) = 165 (pg/ml) (SD 155,
n = 24) compared to mean (NT) = 1310 (pg/ml) (SD 1510, n = 35)
[t(57) = 2.27, P = 0.06]. Levels of the anti-inflammatory cytokine
IL-10 increased noticeably over the first 2 h of perfusion in the
transplanted group, with high initial fold changes in both perfus-
ate and BALF (Fig. 4). Perfusate levels then diminished and were
less than half those in non-transplanted lungs when measured
over the full assessment: mean (T) = 9 (pg/ml) (SD 11, n = 24)
compared to mean (NT) = 23 (pg/ml) (SD 32, n = 40) [t(57) = 2.02,
P = 0.07]. No difference in levels of IL-10 in BALF was seen be-
tween the groups.
A panel of three damage-associated molecular patterns, IL-33,
HMGB-1 and S100A9, was used to assess the extent of cellular in-
jury in the donor lung. Lower levels of IL-33 and HMGB-1 were
found in perfusate from transplanted donor lungs. The average
IL-33 levels in perfusate were mean (T) = 3 (pg/ml) (SD 5, n = 24)
and mean (NT) = 9 (pg/ml) (SD 10, n = 40) [t(62) = 2.93, P = 0.02].
HMGB-1 was highly expressed in both perfusate and BALF. The
HMGB-1 levels in perfusate were mean (T) = 8318 (pg/ml) (SD
4474, n = 24) and mean (NT) = 10 545 (pg/ml) (SD 4,313, n = 40)
[t(62) = 2.10, P = 0.07]. No difference in lavage fluid levels of IL-33
or HMGB-1 was seen between the groups.
We noted a consistent pattern towards increasing perfusate
protein levels and a more pronounced separation between trans-
planted and non-transplanted lungs over time of perfusion
(Fig. 2). This pattern was most noticeable for the investigated in-
flammatory cytokines. The only protein marker not showing this
pattern was S100A9, which appeared lower in the non-
transplanted group.
A multivariate analysis model was fitted to assess the predictive
value of combining two or more protein markers. The optimal
model was established by leave-one-out cross-validation and is
shown in Fig. 5 as a scatterplot of IL-1b and IL-8 perfusate levels
from the 16 assessments. The shaded prediction region was
derived from the regression analysis with covariates IL-1b, IL-8
and (IL-8)2 after 2 h of perfusion. The model suggests that the
closer to the centre of the area, the higher was the probability of
a donor lung being found suitable for transplant after EVLP as-
sessment. This early IL-1b–IL-8 signature remained equally as ro-
bust when applied to the full set of samples (Fig. 5B). An ROC
curve showing the potential benefit of the model in predicting
EVLP outcome compared to random is shown in Fig. 5C, with a
sensitivity of 0.81 and specificity of 0.92 at 2 h of perfusion.
Figure 3: Protein expressions in perfusate and BALF from transplanted and non-transplanted EVLP donor lungs. Interleaved scatter plots with molecular marker levels
expressed in (pg/ml) and lines representing means. *P<0.1. **P<0.05. ***P<0.001. BALF: bronchoalveolar lavage fluid; EVLP: ex vivo lung perfusion; IL: interleukin; TNF-
a: tumour necrosis factor alpha; LDH: lactate dehydrogenase; HMGB-1: high-mobility group box-1.
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The modelled proteins were lastly assessed for correlations to
post-transplant outcome measures. Donor IL-1b levels in the
perfusate at time of transplant decision showed a significant
negative correlation to recipient PaO2:FiO2 24 h post-transplant
(r = -093, P = 0.03) (Fig. 6). No other correlations remained signifi-
cant after corrections for multiple testing in this cohort.
DISCUSSION
In this proof-of-concept study, the feasibility of using inflamma-
tion and tissue injury markers in both perfusate and BALF from
human donor lungs undergoing EVLP to validate the decision to
use or decline them for clinical transplant was evaluated. All 16
donor lungs in this study were assessed consecutively with intent
for transplant following a strict protocol with predefined criteria
for EVLP and transplant suitability to reduce the risk of bias in de-
cision making. All protein analyses were done retrospectively and
had no impact on the transplant decision. Our results demon-
strate a difference in protein expression in perfusate from lungs
that were transplanted compared with those that were declined.
This difference became more apparent for each hour of perfu-
sion, and BALF samples showed a comparable but weaker signal
from the airway compartment.
The difference in donor lungs was effectively demonstrated by a
logistic regression model combining inflammatory cytokines IL-1b
and IL-8 after 2 h of perfusion. The model revealed a clear separ-
ation of the transplanted lungs from those declined. Importantly,
the model remained equally as robust when applied to perfusate
samples from all time points. Furthermore, perfusate IL-1b con-
centrations in transplanted lungs demonstrated a clear negative
correlation to early recipient oxygenation post-transplant.
Even though our results are noteworthy, overinterpretation of
this regression model should be avoided at this stage. Further in-
vestigations are required to assess its biological plausibility. A few
declined lungs displayed a very low IL-1b/IL-8 signal—below that
Figure 4: Protein median fold changes in perfusate and BALF from EVLP donor lungs. Bar graphs showing median fold changes with interquartile range. BALF: bron-
choalveolar lavage fluid; EVLP: ex vivo lung perfusion; IL: interleukin; TNF-a: tumour necrosis factor alpha; LDH: lactate dehydrogenase; HMGB-1: high-mobility group
box-1.
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of lungs deemed reconditioned and transplanted with good out-
comes after the EVLP assessment. If this finding indicates that
those lungs were wrongfully declined and could safely have been
transplanted, that EVLP-assessed lungs deemed suitable for trans-
plant truly express an intermediate level of inflammation, or that
this is a signal specific to this relatively small cohort needs further
assessment in follow-up studies.
The measurement of LDH levels in perfusate had the potential
to significantly predict EVLP outcome as early as 2 h into perfu-
sion. Although real-time ligand binding assays for inflammatory
cytokines and other tissue injury markers may soon become ac-
cessible [22], LDH has the benefit of being a widely recognized
marker of tissue injury in serum and BALF and rapidly available
as a point-of-care test [23, 24].
The Brisbane lung transplant group have described measures
of endothelial dysfunction as potentially useful in EVLP [25, 26].
Our results strengthen that belief. Syndecan-1, released by dis-
ruption of the endothelial glycocalyx, may be a discriminatory
marker in EVLP perfusate and should be further evaluated.
Increasing levels of inflammatory cytokines in perfusate and
tissue have been shown during experimental lung perfusion in
porcine models and a small preclinical human lung study, which
might reflect procedure-mediated inflammation [27–29]. Our
findings during full clinical EVLP support recent observations
made by Machuca and colleagues [30] from Toronto and demon-
strate the feasibility of identifying biomarkers that might improve
EVLP assessment.
IL-8, proposed as one of the best markers of EVLP transplant
outcome in the Machuca study, has consistently shown potential
in previous studies of donor lung injury from our group [12, 13].
The potential of IL-8 to discriminate successful EVLP in our study
was enhanced by combining it with IL-1b.
Figure 5: (A) Early IL-1b-IL-8 signature in EVLP perfusate after 2 h of perfusion. (B) IL-1b-IL-8 signature in EVLP perfusate after full assessment. (C) ROC curve. (A) and
(B) Scatter plots of IL-1b and IL-8 levels in perfusate samples from transplanted and non-transplanted EVLP donor lungs. The shaded area is the prediction region
from the optimal logistic regression model with covariates IL-1b, IL-8 and (IL-8)2. (C) Receiver operating characteristic (ROC) curve of the model as a predictor of EVLP
outcome. Calculated sensitivity (y axis) is plotted against the 1-specificity formula (x axis) of the logistic regression function 2 h into perfusion and after full assessment.
EVLP: ex vivo lung perfusion; IL: interleukin.
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Our observations add significantly to previous observations
because we have included an assessment of BALF inflammatory
and tissue injury markers compared to EVLP perfusate measures.
Even though BALF samples in this study did not add any appar-
ent clinical value to perfusate sampling, we feel it is too early to
draw any firm conclusions, and we will continue to assess a
broad spectrum of markers and lung compartment samples in fu-
ture studies. In addition, because protein levels are measured in a
fixed volume of 2 litres of perfusate solution, we corrected pro-
tein levels for the size of lung tissue perfused. This potential con-
founder has been disregarded in previous studies. The pTLC of
the donor lung ranged from 4.31 to 7.54 litres among the double
lungs perfused, and the smallest single lung had a pTLC of only
2.70 litres. Unadjusted marker levels are therefore likely to differ
widely between donor lungs regardless of the degree of lung in-
jury present.
A limitation of our study is its relatively small sample size, with
16 human EVLP assessments included, yet this number is suffi-
cient to demonstrate the feasibility of using perfusate markers to
discriminate successful EVLP. Outcomes were almost universally
good, and this study does not identify predictors of early lung in-
jury. Larger studies, with a cohort of patients doing less well, are
needed to address that particular question. Caution is, however,
required in overinterpretation of moderate to severe PGD (Grade
2–3) after transplant as a reason for donor lungs to be declined
after EVLP, because many recipients with PGD 2–3 will recover
and have satisfactory early outcomes.
Truly marginal donor lungs subjected to EVLP for recondition-
ing purposes form by nature a subpopulation that is likely to
have a higher inflammatory burden than standard donor lungs.
We believe that biomarker profiles of these lungs could help sup-
port the clinical decision to use or decline the donor lungs after
EVLP and allow continued safe transplant activity. Furthermore,
this approach offers the potential to attenuate the inflammatory
response or encourage recovery of vascular integrity in the donor
lung before implantation in a stratified medicine approach,
which may improve early outcomes after lung transplant and
help to safely maximize lung use from the existing donor pool.
The results of this study need further evaluation in a larger val-
idation cohort of lungs exposed to ex vivo perfusion but demon-
strate the feasibility of identifying an early perfusate signature
potentially predictive of successful EVLP reconditioning.
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